Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model

In the hepatitis B virus (HBV)-related hepatocellular carcinoma tumor microenvironment (TME), monocytes reportedly impede natural T cell functions via PD-L1/PD-1 signaling. However, it remains unclear if T cell receptor-redirected T cells (TCR T cells) are similarly inhibited. Hence, we developed a 3D intrahepatic TME microfluidic model to investigate the immunosuppressive potential of monocytes toward HBV-specific TCR T cells and the role of PD-L1/PD-1 signaling. Interestingly, in our 3D static microfluidic model, we observed that monocytes suppressed only retrovirally transduced (Tdx) TCR T cell cytotoxicity toward cancer cells via PD-L1/PD-1, while mRNA electroporated (EP) TCR T cell cytotoxicity was not affected by the presence of monocytes. Importantly, when co-cultured in 2D, both Tdx and EP TCR T cell cytotoxicity toward cancer cells were not suppressed by monocytes, suggesting our 3D model as a superior tool compared to standard 2D assays for predicting TCR T cell efficacy in a preclinical setting, which can thus be used to improve current immunotherapy strategies.

[1]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[2]  Roger D. Kamm,et al.  A 3D neurovascular microfluidic model consisting of neurons, astrocytes and cerebral endothelial cells as a blood-brain barrier. , 2017, Lab on a chip.

[3]  D. Campana,et al.  A Practical Approach to Immunotherapy of Hepatocellular Carcinoma Using T Cells Redirected Against Hepatitis B Virus , 2013, Molecular therapy. Nucleic acids.

[4]  Andrea Pavesi,et al.  A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. , 2017, JCI insight.

[5]  V. Gelfanov,et al.  IL-15 Promotes Survival But Not Effector Function Differentiation of CD8+ TCRαβ+ Intestinal Intraepithelial Lymphocytes , 1999, The Journal of Immunology.

[6]  A. Bertoletti,et al.  Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. , 2015, Journal of hepatology.

[7]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[8]  A. Fauci,et al.  The Common γ-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands , 2008, The Journal of Immunology.

[9]  A. Doseff,et al.  Monocyte Subsets and Their Role in Tumor Progression , 2012 .

[10]  A. Pavesi,et al.  Using microfluidics to investigate tumor cell extravasation and T-cell immunotherapies , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[11]  Andrea Pavesi,et al.  Advances in microfluidics in combating infectious diseases , 2016, Biotechnology Advances.

[12]  T. Tsai,et al.  Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. , 2016, World journal of gastroenterology.

[13]  B. Ksander,et al.  Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80 , 2011, The Journal of Immunology.

[14]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[15]  Roger D. Kamm,et al.  Rapid Prototyping of Concave Microwells for the Formation of 3D Multicellular Cancer Aggregates for Drug Screening , 2013, Advanced healthcare materials.

[16]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[17]  Roger D Kamm,et al.  Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[18]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[19]  K. Odunsi,et al.  Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer , 2016, Oncoimmunology.

[20]  Andrea Pavesi,et al.  Microfluidic models for adoptive cell-mediated cancer immunotherapies. , 2016, Drug discovery today.

[21]  Roger D. Kamm,et al.  Contact-dependent carcinoma aggregate dispersion by M2a macrophages via ICAM-1 and β2 integrin interactions , 2015, Oncotarget.

[22]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[23]  M. J. You,et al.  The Role of Tumor-Associated Macrophages in Leukemia , 2019, Acta Haematologica.

[24]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[25]  A. Elia,et al.  T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors. , 2017, Cancer research.

[26]  P. Frosch,et al.  Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: comparison between two- and three-dimensional culture. , 1994, International Journal of Cancer.

[27]  V. Gelfanov,et al.  IL-15 promotes survival but not effector function differentiation of CD8+ TCRalphabeta+ intestinal intraepithelial lymphocytes. , 1999, Journal of immunology.

[28]  M. Grompe,et al.  Extensive double humanization of both liver and hematopoiesis in FRGN mice , 2014, Stem cell research.

[29]  V. Boussiotis,et al.  Biochemical Signaling of PD-1 on T Cells and Its Functional Implications , 2014, Cancer journal.

[30]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[31]  R. Kamm,et al.  Microfluidic assay for simultaneous culture of multiple cell types on surfaces or within hydrogels , 2012, Nature Protocols.

[32]  R. Davis,et al.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[33]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Cloughesy,et al.  Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma , 2017, Neuro-oncology.

[35]  Roger D. Kamm,et al.  M2a macrophages induce contact-dependent dispersion of carcinoma cell aggregates , 2016 .

[36]  James P. Freyer,et al.  The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model , 2004, Journal of biomolecular screening.

[37]  Jiasen Cheng,et al.  Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. , 2007, Blood.

[38]  J. Gulley,et al.  Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer. , 2014, Translational lung cancer research.

[39]  Roger Williams,et al.  Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. , 2015, Gastroenterology.

[40]  A. Bertoletti,et al.  Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. , 2011, Journal of hepatology.

[41]  F. Ginhoux,et al.  Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma , 2016, Oncoimmunology.

[42]  Ton N. Schumacher,et al.  Adoptive cellular therapy: A race to the finish line , 2015, Science Translational Medicine.

[43]  G. Freeman,et al.  PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status , 2007, AIDS.

[44]  H. Acker,et al.  Effects of nIFN β and rifn γ on growth and morphology of two human melanoma cell lines: Comparison between two‐and three‐dimensional culture , 1994 .

[45]  F. Q. Ribeiro The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[46]  J. Larrubia,et al.  Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. , 2016, World journal of gastroenterology.

[47]  R. Kamm,et al.  Microfluidics: A new tool for modeling cancer-immune interactions. , 2016, Trends in cancer.

[48]  S. Qiu,et al.  Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.

[49]  F. Hodi,et al.  Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 , 2012, Clinical Cancer Research.

[50]  Tobias Schmelzle,et al.  Engineering tumors with 3D scaffolds , 2007, Nature Methods.

[51]  D. Tamang,et al.  Low dose IL-15 induces snap arming of CD44(low) T lymphocytes in the absence of antigen. , 2008, Cellular immunology.

[52]  Qing He,et al.  CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia , 2013, Science Translational Medicine.

[53]  P. Tien,et al.  PD‐1 and PD‐L1 upregulation promotes CD8+ T‐cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients , 2011, International journal of cancer.

[54]  Alison P McGuigan,et al.  The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery? , 2018, Advanced healthcare materials.

[55]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[57]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[58]  R. Krance,et al.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.

[59]  W. Liang,et al.  Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer , 2015, Medicine.

[60]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[61]  Roger D. Kamm,et al.  Modeling the Blood-Brain Barrier in a 3D triple co-culture microfluidic system , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[62]  M. Bruno,et al.  Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. , 2017, Gastroenterology.

[63]  F. Ginhoux,et al.  Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. , 2017, Journal of hepatology.

[64]  M. Nishimura,et al.  Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death. , 2016, Cancer research.

[65]  Jing Xu,et al.  Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 , 2009, The Journal of experimental medicine.

[66]  H. Shiku,et al.  Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia. , 2013, Blood.

[67]  Zhi Chen,et al.  PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. , 2008, Molecular immunology.

[68]  M. Poupon,et al.  Distinctive alterations of invasiveness, drug resistance and cell–cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant , 2004, Clinical & Experimental Metastasis.

[69]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[70]  N. Restifo,et al.  Cellular constituents of immune escape within the tumor microenvironment. , 2012, Cancer research.

[71]  J. Pollard,et al.  Immune cell promotion of metastasis , 2015, Nature Reviews Immunology.

[72]  J. Mcclendon “Race” to the Finish Line , 2017 .

[73]  R. Kamm,et al.  A Facile Method to Probe the Vascular Permeability of Nanoparticles in Nanomedicine Applications , 2017, Scientific Reports.

[74]  P. Allavena,et al.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. , 2008, Critical reviews in oncology/hematology.

[75]  Roger D. Kamm,et al.  Engineering a 3D microfluidic culture platform for tumor-treating field application , 2016, Scientific Reports.

[76]  N. Mitsiades,et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. , 1999, The Journal of clinical endocrinology and metabolism.